Cargando…

Fibrotic Encapsulation Is the Dominant Source of Continuous Glucose Monitor Delays

Continuous glucose monitor (CGM) readings are delayed relative to blood glucose, and this delay is usually attributed to the latency of interstitial glucose levels. However, CGM-independent data suggest rapid equilibration of interstitial glucose. This study sought to determine the loci of CGM delay...

Descripción completa

Detalles Bibliográficos
Autores principales: McClatchey, P. Mason, McClain, Ethan S., Williams, Ian M., Malabanan, Carlo M., James, Freyja D., Lord, Peter C., Gregory, Justin M., Cliffel, David E., Wasserman, David H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754243/
https://www.ncbi.nlm.nih.gov/pubmed/31399432
http://dx.doi.org/10.2337/db19-0229
_version_ 1783453048088035328
author McClatchey, P. Mason
McClain, Ethan S.
Williams, Ian M.
Malabanan, Carlo M.
James, Freyja D.
Lord, Peter C.
Gregory, Justin M.
Cliffel, David E.
Wasserman, David H.
author_facet McClatchey, P. Mason
McClain, Ethan S.
Williams, Ian M.
Malabanan, Carlo M.
James, Freyja D.
Lord, Peter C.
Gregory, Justin M.
Cliffel, David E.
Wasserman, David H.
author_sort McClatchey, P. Mason
collection PubMed
description Continuous glucose monitor (CGM) readings are delayed relative to blood glucose, and this delay is usually attributed to the latency of interstitial glucose levels. However, CGM-independent data suggest rapid equilibration of interstitial glucose. This study sought to determine the loci of CGM delays. Electrical current was measured directly from CGM electrodes to define sensor kinetics in the absence of smoothing algorithms. CGMs were implanted in mice, and sensor versus blood glucose responses were measured after an intravenous glucose challenge. Dispersion of a fluorescent glucose analog (2-NBDG) into the CGM microenvironment was observed in vivo using intravital microscopy. Tissue deposited on the sensor and nonimplanted subcutaneous adipose tissue was then collected for histological analysis. The time to half-maximum CGM response in vitro was 35 ± 2 s. In vivo, CGMs took 24 ± 7 min to reach maximum current versus 2 ± 1 min to maximum blood glucose (P = 0.0017). 2-NBDG took 21 ± 7 min to reach maximum fluorescence at the sensor versus 6 ± 6 min in adipose tissue (P = 0.0011). Collagen content was closely correlated with 2-NBDG latency (R = 0.96, P = 0.0004). Diffusion of glucose into the tissue deposited on a CGM is substantially delayed relative to interstitial fluid. A CGM that resists fibrous encapsulation would better approximate real-time deviations in blood glucose.
format Online
Article
Text
id pubmed-6754243
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-67542432020-10-01 Fibrotic Encapsulation Is the Dominant Source of Continuous Glucose Monitor Delays McClatchey, P. Mason McClain, Ethan S. Williams, Ian M. Malabanan, Carlo M. James, Freyja D. Lord, Peter C. Gregory, Justin M. Cliffel, David E. Wasserman, David H. Diabetes Technological Advances Continuous glucose monitor (CGM) readings are delayed relative to blood glucose, and this delay is usually attributed to the latency of interstitial glucose levels. However, CGM-independent data suggest rapid equilibration of interstitial glucose. This study sought to determine the loci of CGM delays. Electrical current was measured directly from CGM electrodes to define sensor kinetics in the absence of smoothing algorithms. CGMs were implanted in mice, and sensor versus blood glucose responses were measured after an intravenous glucose challenge. Dispersion of a fluorescent glucose analog (2-NBDG) into the CGM microenvironment was observed in vivo using intravital microscopy. Tissue deposited on the sensor and nonimplanted subcutaneous adipose tissue was then collected for histological analysis. The time to half-maximum CGM response in vitro was 35 ± 2 s. In vivo, CGMs took 24 ± 7 min to reach maximum current versus 2 ± 1 min to maximum blood glucose (P = 0.0017). 2-NBDG took 21 ± 7 min to reach maximum fluorescence at the sensor versus 6 ± 6 min in adipose tissue (P = 0.0011). Collagen content was closely correlated with 2-NBDG latency (R = 0.96, P = 0.0004). Diffusion of glucose into the tissue deposited on a CGM is substantially delayed relative to interstitial fluid. A CGM that resists fibrous encapsulation would better approximate real-time deviations in blood glucose. American Diabetes Association 2019-10 2019-08-09 /pmc/articles/PMC6754243/ /pubmed/31399432 http://dx.doi.org/10.2337/db19-0229 Text en © 2019 by the American Diabetes Association. http://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.
spellingShingle Technological Advances
McClatchey, P. Mason
McClain, Ethan S.
Williams, Ian M.
Malabanan, Carlo M.
James, Freyja D.
Lord, Peter C.
Gregory, Justin M.
Cliffel, David E.
Wasserman, David H.
Fibrotic Encapsulation Is the Dominant Source of Continuous Glucose Monitor Delays
title Fibrotic Encapsulation Is the Dominant Source of Continuous Glucose Monitor Delays
title_full Fibrotic Encapsulation Is the Dominant Source of Continuous Glucose Monitor Delays
title_fullStr Fibrotic Encapsulation Is the Dominant Source of Continuous Glucose Monitor Delays
title_full_unstemmed Fibrotic Encapsulation Is the Dominant Source of Continuous Glucose Monitor Delays
title_short Fibrotic Encapsulation Is the Dominant Source of Continuous Glucose Monitor Delays
title_sort fibrotic encapsulation is the dominant source of continuous glucose monitor delays
topic Technological Advances
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754243/
https://www.ncbi.nlm.nih.gov/pubmed/31399432
http://dx.doi.org/10.2337/db19-0229
work_keys_str_mv AT mcclatcheypmason fibroticencapsulationisthedominantsourceofcontinuousglucosemonitordelays
AT mcclainethans fibroticencapsulationisthedominantsourceofcontinuousglucosemonitordelays
AT williamsianm fibroticencapsulationisthedominantsourceofcontinuousglucosemonitordelays
AT malabanancarlom fibroticencapsulationisthedominantsourceofcontinuousglucosemonitordelays
AT jamesfreyjad fibroticencapsulationisthedominantsourceofcontinuousglucosemonitordelays
AT lordpeterc fibroticencapsulationisthedominantsourceofcontinuousglucosemonitordelays
AT gregoryjustinm fibroticencapsulationisthedominantsourceofcontinuousglucosemonitordelays
AT cliffeldavide fibroticencapsulationisthedominantsourceofcontinuousglucosemonitordelays
AT wassermandavidh fibroticencapsulationisthedominantsourceofcontinuousglucosemonitordelays